2012年ACOG临床指南131：子宫颈癌筛查指南（更新版）
ACOG Practice Bulletin Number 131: Screening for cervical cancer.
2012-11-01
《2012年ACOG临床指南131：子宫颈癌筛查指南》是美国妇产科医师学会对2009年12月第109号指南的更新版。The incidence of cervical cancer in the United States has decreased more than 50% in the past 30 years because ofwidespread screening with cervical cytology. In 1975, the rate was 14.8 per 100,000 women. By 2008, it had beenreduced to 6.6 per 100,000 women. Mortality from the disease has undergone a similar decrease from 5.55 per100,000 women in 1975 to 2.38 per 100,000 women in 2008 (1). The American Cancer Society (ACS) estimates thatthere will be 12,170 new cases of cervical cancer in the United States in 2012, with 4,220 deaths from the disease(2). Cervical cancer is much more common worldwide, particularly in countries without screening programs, withan estimated 530,000 new cases of the disease and 275,000 resultant deaths each year (3, 4). When cervical cancerscreening programs have been introduced into communities, marked reductions in cervical cancer incidence havefollowed (5, 6).New technologies for cervical cancer screening continue to evolve as do recommendations for managing the results.In addition, there are different risk–benefit considerations for women at different ages, as reflected in age-specificscreening recommendations. The ACS, the American Society for Colposcopy and Cervical Pathology (ASCCP), andthe American Society for Clinical Pathology (ASCP) have recently updated their joint guidelines for cervical cancerscreening (7), and an update to the U.S. Preventive Services Task Force recommendations also has been issued (8).The purpose of this document is to provide a review of the best available evidence regarding screening for cervicalcancer.(Replaces Practice Bulletin Number 109, December 2009)
